Targeted 1,3-dipolar cycloaddition with acrolein for cancer prodrug activation

Cytotoxic anticancer drugs used in chemotherapy are often antiproliferative agents that preferentially kill rapidly growing cancer cells. Their mechanism relies mainly on the enhanced proliferation rate of cancer cells and is not genuinely selective for cancer cells. Therefore, these drugs can also...

Full description

Saved in:
Bibliographic Details
Published in:Chemical science (Cambridge) 2021-04, Vol.12 (15), p.5438-5449
Main Authors: Pradipta, Ambara R, Ahmadi, Peni, Terashima, Kazuki, Muguruma, Kyohei, Fujii, Motoko, Ichino, Tomoya, Maeda, Satoshi, Tanaka, Katsunori
Format: Article
Language:English
Subjects:
Acrolein
Cancer therapies
Chemistry
Chemotherapy
Cycloaddition
Cytotoxicity
Drugs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytotoxic anticancer drugs used in chemotherapy are often antiproliferative agents that preferentially kill rapidly growing cancer cells. Their mechanism relies mainly on the enhanced proliferation rate of cancer cells and is not genuinely selective for cancer cells. Therefore, these drugs can also significantly affect healthy cells. Prodrug therapy provides an alternative approach using a less cytotoxic form of anticancer drug. It involves the synthesis of inactive drug derivatives which are converted to an active form inside the body and, preferably, only at the site of cancerous tissues, thereby reducing adverse drug reaction (ADR) events. Herein, we demonstrate a prodrug activation strategy by utilizing the reaction between aryl azide and endogenous acrolein. Since acrolein is generally overproduced by most cancer cells, we anticipate our strategy as a starting point for further applications in mouse models with various cancers. Furthermore, cancer drugs that have had therapeutic index challenges might be reconsidered for application by utilizing our strategy. Prodrug activation strategy by utilizing the reaction between aryl azide and endogenous acrolein that is generally overproduced by cancer cells.
ISSN:2041-6520
2041-6539
DOI:10.1039/d0sc06083f